Clinical Trials · NCT06821100
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- The Methodist Hospital Research Institute
- Enrollment
- 75
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]